Drug Trial Radar · NCT07918898
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
26
Planned (sponsor's estimate)
Start
Nov 2, 2026
Primary completion
Feb 2, 2027
Study completion Feb 2, 2027
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial is conducted in China. This study will be conducted to evaluate pharmacokinetic/pharmacodynamic characteristics and safety of single administration of GZR101-80 Injection with separately injected, simultaneous doses of GZR33 Injection and Insulin Aspart in healthy participants
Conditions
- Healthy Participants
Interventions
GZR101 80 InjectionDrug
Single dose. Administered s.c.
GZR33 InjectionDrug
Single dose. Administered s.c.
Insulin Aspart InjectionDrug
Single dose. Administered s.c.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCIAsp,0-6hTime frame: 0-6 hours after dosing
- AUC GZR33, 0-24hTime frame: 0-24 hours after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Ethics Committee of Bishan Hospital of Chongqing
Chongqing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.